Medtech startup Magnendo announced on February 11 that it had received investment from Base Ventures and Kakao Ventures. The investments were made in the pre-seed and pre-seed bridge stages, respectively.
Magnendo is developing innovative technologies that can perform brain nerve treatment faster and more safely by utilizing robotic technology. The company's core technology, 'Magnetic Steering & Navigation', helps to safely access the inside of blood vessels that are difficult to access with existing treatment methods.
With this investment, Magnendo plans to accelerate its research on robot platforms related to brain nerve treatment and strengthen its collaboration with medical institutions. It also plans to expand its technology to various application areas such as remote treatment and create a new standard for brain nerve treatment.
Kakao Ventures’ Senior Analyst Shin Jeong-ho explained the reason for the investment, saying, “CEO Kim Yoon-ho, who achieved excellent research results at MIT, is an expert who has verified robotics platforms with multinational corporate partners, and the fact that he has brought key leaders with experience in business development and regulatory response at global medical robot companies to the team is a major strength.”
“Magnendo’s technology is an innovative solution that will overcome the limitations of existing neurovascular procedures,” said Dong-eon Choi, Senior Team Leader at Base Ventures. “In the global market where remote treatment and automated surgery are gaining attention, we expect Magnendo’s robotic technology to create a new standard of treatment.”
“We will continue to innovate so that both patients and medical professionals can achieve better outcomes in neurological treatment,” said Kim Yun-ho, CEO of Magnendo.
- See more related articles
You must be logged in to post a comment.